vs

Side-by-side financial comparison of C4 Therapeutics, Inc. (CCCC) and EMPIRE PETROLEUM CORP (EP). Click either name above to swap in a different company.

C4 Therapeutics, Inc. is the larger business by last-quarter revenue ($11.0M vs $7.1M, roughly 1.6× EMPIRE PETROLEUM CORP). C4 Therapeutics, Inc. runs the higher net margin — -186.0% vs -835.1%, a 649.2% gap on every dollar of revenue. On growth, C4 Therapeutics, Inc. posted the faster year-over-year revenue change (112.8% vs -30.0%). Over the past eight quarters, C4 Therapeutics, Inc.'s revenue compounded faster (90.4% CAGR vs -13.3%).

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted protein degradation therapies for cancer and other severe diseases with high unmet medical needs. It leverages its proprietary TORPEDO platform to design small molecule degraders that eliminate disease-causing proteins, with a pipeline of oncology candidates in preclinical and clinical development, plus strategic partnerships with leading global pharmaceutical firms.

The Iraq Petroleum Company (IPC), formerly known as the Turkish Petroleum Company (TPC), is an oil company that had a virtual monopoly on all oil exploration and production in Iraq between 1925 and 1961. It was jointly owned by some of the world's largest oil companies and headquartered in London, England.

CCCC vs EP — Head-to-Head

Bigger by revenue
CCCC
CCCC
1.6× larger
CCCC
$11.0M
$7.1M
EP
Growing faster (revenue YoY)
CCCC
CCCC
+142.8% gap
CCCC
112.8%
-30.0%
EP
Higher net margin
CCCC
CCCC
649.2% more per $
CCCC
-186.0%
-835.1%
EP
Faster 2-yr revenue CAGR
CCCC
CCCC
Annualised
CCCC
90.4%
-13.3%
EP

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CCCC
CCCC
EP
EP
Revenue
$11.0M
$7.1M
Net Profit
$-20.5M
$-59.0M
Gross Margin
Operating Margin
-210.1%
-834.5%
Net Margin
-186.0%
-835.1%
Revenue YoY
112.8%
-30.0%
Net Profit YoY
40.7%
-1306.0%
EPS (diluted)
$-0.09
$-1.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CCCC
CCCC
EP
EP
Q4 25
$11.0M
$7.1M
Q3 25
$11.2M
$9.4M
Q2 25
$6.5M
$8.8M
Q1 25
$7.2M
$9.0M
Q4 24
$5.2M
$10.1M
Q3 24
$15.4M
$11.4M
Q2 24
$12.0M
$12.8M
Q1 24
$3.0M
$9.4M
Net Profit
CCCC
CCCC
EP
EP
Q4 25
$-20.5M
$-59.0M
Q3 25
$-32.2M
$-3.8M
Q2 25
$-26.0M
$-5.1M
Q1 25
$-26.3M
$-4.2M
Q4 24
$-34.6M
$-4.2M
Q3 24
$-24.7M
$-3.6M
Q2 24
$-17.7M
$-4.4M
Q1 24
$-28.4M
$-4.0M
Operating Margin
CCCC
CCCC
EP
EP
Q4 25
-210.1%
-834.5%
Q3 25
-306.4%
-37.8%
Q2 25
-441.0%
-56.0%
Q1 25
-402.9%
-43.9%
Q4 24
-728.4%
-38.9%
Q3 24
-183.9%
-30.0%
Q2 24
-178.6%
-15.0%
Q1 24
-1060.2%
-46.8%
Net Margin
CCCC
CCCC
EP
EP
Q4 25
-186.0%
-835.1%
Q3 25
-286.4%
-40.9%
Q2 25
-402.6%
-57.8%
Q1 25
-363.7%
-46.9%
Q4 24
-667.8%
-41.6%
Q3 24
-160.6%
-32.0%
Q2 24
-147.6%
-34.3%
Q1 24
-933.2%
-42.3%
EPS (diluted)
CCCC
CCCC
EP
EP
Q4 25
$-0.09
$-1.74
Q3 25
$-0.44
$-0.11
Q2 25
$-0.37
$-0.15
Q1 25
$-0.37
$-0.12
Q4 24
$-0.50
$-0.12
Q3 24
$-0.35
$-0.12
Q2 24
$-0.26
$-0.15
Q1 24
$-0.41
$-0.15

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CCCC
CCCC
EP
EP
Cash + ST InvestmentsLiquidity on hand
$74.6M
$1.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$256.6M
$-4.6M
Total Assets
$359.1M
$65.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CCCC
CCCC
EP
EP
Q4 25
$74.6M
$1.2M
Q3 25
$58.8M
$4.6M
Q2 25
$78.2M
$2.3M
Q1 25
$51.3M
$1.1M
Q4 24
$55.5M
$2.3M
Q3 24
$59.6M
$3.1M
Q2 24
$73.1M
$9.3M
Q1 24
$89.7M
$3.5M
Total Debt
CCCC
CCCC
EP
EP
Q4 25
Q3 25
$15.2M
Q2 25
$14.6M
Q1 25
$11.6M
Q4 24
$11.3M
Q3 24
$8.5M
Q2 24
$8.5M
Q1 24
$8.5M
Stockholders' Equity
CCCC
CCCC
EP
EP
Q4 25
$256.6M
$-4.6M
Q3 25
$154.4M
$53.7M
Q2 25
$174.1M
$54.5M
Q1 25
$195.1M
$59.1M
Q4 24
$216.0M
$62.8M
Q3 24
$242.7M
$56.5M
Q2 24
$247.1M
$58.7M
Q1 24
$258.3M
$31.7M
Total Assets
CCCC
CCCC
EP
EP
Q4 25
$359.1M
$65.9M
Q3 25
$265.5M
$123.0M
Q2 25
$296.5M
$124.7M
Q1 25
$319.5M
$123.7M
Q4 24
$349.6M
$123.9M
Q3 24
$376.1M
$121.2M
Q2 24
$381.1M
$119.9M
Q1 24
$398.4M
$100.1M
Debt / Equity
CCCC
CCCC
EP
EP
Q4 25
Q3 25
0.28×
Q2 25
0.27×
Q1 25
0.20×
Q4 24
0.18×
Q3 24
0.15×
Q2 24
0.15×
Q1 24
0.27×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CCCC
CCCC
EP
EP
Operating Cash FlowLast quarter
$-22.1M
$-2.8M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CCCC
CCCC
EP
EP
Q4 25
$-22.1M
$-2.8M
Q3 25
$-31.2M
$330.0K
Q2 25
$-12.1M
$-3.1M
Q1 25
$-33.3M
$1.6M
Q4 24
$-17.9M
$-8.8M
Q3 24
$-24.1M
$12.8M
Q2 24
$-5.0M
$-1.8M
Q1 24
$-18.1M
$3.9M
Free Cash Flow
CCCC
CCCC
EP
EP
Q4 25
Q3 25
$-31.6M
Q2 25
Q1 25
Q4 24
$-17.9M
Q3 24
$-24.1M
Q2 24
$-5.2M
Q1 24
FCF Margin
CCCC
CCCC
EP
EP
Q4 25
Q3 25
-281.5%
Q2 25
Q1 25
Q4 24
-346.5%
Q3 24
-157.2%
Q2 24
-43.1%
Q1 24
Capex Intensity
CCCC
CCCC
EP
EP
Q4 25
Q3 25
3.7%
Q2 25
Q1 25
Q4 24
0.1%
Q3 24
0.1%
Q2 24
1.6%
Q1 24
0.0%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons